To read the full article sign up for free or sign in.

BMS, Eisai join forces for phase I ADC in potential $3B-plus deal

June 22, 2021

Bristol Myers Squibb Co. and Eisai Co. Ltd. inked a potential $3.1 billion agreement to co-develop and co-commercialize the antibody-drug conjugate MORAb-202 for advanced solid tumors.

BioWorld Asia Deals and M&A Cancer Antibody-drug conjugate Japan

Today's news in brief

BioWorld

BioWorld briefs for May 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for May 9, 2025.

US flag, stock market chart, White House

100 days of uncertainty

BioWorld

The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...

Tenvie Therapeutics discovers new TMEM175 modulators

BioWorld Science

Tenvie Therapeutics Inc. has described endosomal/lysosomal proton channel TMEM175 modulators reported to be useful for the treatment of cancer, neurological...

AI generated, 3D rendering of protein degradation

AACR 2025: Induced proximity strategy, beyond degraders

BioWorld

Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...